DesRosier Thomas 4
4 · Seres Therapeutics, Inc. · Filed Jul 10, 2026
Research Summary
AI-generated summary of this filing
Seres (MCRB) EVP Thomas DesRosier Receives 7,500-Share Award
What Happened Thomas DesRosier, EVP and Chief Legal Officer of Seres Therapeutics (MCRB), was granted a derivative equity award on July 8, 2026 for 7,500 shares at $0.00 per share (transaction code A). The filing identifies the award as an option; no cash was paid at grant. This is a compensation grant, not an open-market purchase or sale.
Key Details
- Transaction date and type: 2026-07-08 — Grant of a derivative award (code A).
- Quantity and price: 7,500 shares, $0.00 per share (grant value recorded as $0 in the filing).
- Vesting: Footnote states the option vests 25% on March 2, 2027, with the remainder vesting in 12 equal quarterly installments thereafter.
- Shares owned after transaction: Not specified in the filing.
- Timeliness: Reported on Form 4 filed 2026-07-10 for the 2026-07-08 grant (appears timely).
- Role: DesRosier is EVP and Chief Legal Officer (listed in remarks).
Context This was an equity compensation grant (an option) subject to future vesting based on continued service; it does not reflect an immediate market purchase or sale. Such grants are routine for executive compensation and should be interpreted as part of pay structure rather than a direct trading signal.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-07-08+7,500→ 7,500 totalExercise: $9.13Exp: 2036-03-03→ Common Stock (7,500 underlying)
Footnotes (1)
- [F1]The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter.